Secukinumab

The experimental arms receive reduced secukinumab exposure combined with the conditioned beverage. Treatment-as-usual receives standard secukinumab dosing in the trial. The continuous reinforcement arm uses full-dose acquisition followed by continuous 75 mg secukinumab on the same visit schedule. The partial reinforcement arm uses full-dose acquisition followed by alternating 150 mg secukinumab or placebo on later visits. Patients with contraindications to secukinumab or prior secukinumab treatment are excluded. Participants can access standard secukinumab treatment or another therapy after the study.